Table 3 of
Li, Mol Vis 2022; 28:460-479. Table 3 of
Li, Mol Vis 2022; 28:460-479.
Table 3. Results of each ERG program at 1 and 2 weeks after administration of eye drops.
| Program | Time | Wave | High concentration group | Middle concentration group | Low concentration group | Control group |
|---|---|---|---|---|---|---|
| Dark-adapted 0.01 ERG | 1 w | b-wave (μV) | 101.08±24.61 | 78.93±30.49 | 88.27±17.22 | 107.87±35.92 |
| 2 w | b-wave (μV) | 98.89±42.68 | 83.74±28.84 | 78.53±34.94 | 85.78±41.19 | |
| Dark-adapted 3.0 ERG | 1 w | a-wave (μV) | 41.47±7.89 | 43.28±3.43 | 53.12±13.21 | 50.63±16.95 |
| b-wave (μV) | 101.95±21.96 | 115.48±20.35 | 140.18±48.87 | 148.41±47.22 | ||
| 2 w | a-wave (μV) | 43.71±9.12 | 57.52±10.48 | 40.63±7.46 | 43.00±11.06 | |
| b-wave (μV) | 131.00±35.87 | 148.00±24.36 | 107.50±31.17 | 124.31±34.49 | ||
| Dark-adapted 3.0 oscillatory potential | 1 w | OS2 (μV) | 67.62±31.51 | 70.15±19.01 | 74.76±50.03 | 71.12±29.06 |
| 2 w | OS2 (μV) | 47.80±11.31 | 77.62±27.40 | 39.63±24.04 | 51.34±24.97 | |
| Light-adapted 3.0 ERG | 1 w | a-wave (μV) | 2.78±0.76 | 5.85±4.76 | 3.67±0.95 | 2.15±1.76 |
| b-wave (μV) | 19.00±11.99 | 22.68±4.70 | 24.50±11.96 | 22.13±6.45 | ||
| 2 w | a-wave (μV) | 3.73±1.32 | 3.57±1.52 | 3.37±1.52 | 2.82±1.90 | |
| b-wave (μV) | 18.50±5.08 | 22.84±7.26 | 19.74±4.45 | 20.00±6.77 | ||
| Light-adapted Fare ERG | 1 w | P1-N1 (ms) | 15.68±2.47 | 18.28±2.59 | 16.36±2.02 | 16.64±1.61 |
| P1-N1 (μV) | 5.80±1.55 | 6.18±2.76 | 7.43±1.76 | 5.94±1.99 | ||
| 2 w | P1-N1 (ms) | 18.31±3.16 | 16.06±2.92 | 17.47±4.39 | 18.38±3.64 | |
| P1-N1 (μV) | 4.60±1.40 | 4.75±1.29 | 7.51±2.30 | 5.22±1.66 |